Bill Summary
This is a bill that aims to amend a section of the Controlled Substances Act to eliminate the separate registration requirement for dispensing certain narcotic drugs (such as buprenorphine) for maintenance or detoxification treatment. The bill also includes provisions for conforming changes to related legislation and calls for a national education campaign to encourage practitioners to integrate substance use treatment into their practices.
Possible Impacts
1. This legislation could potentially affect individuals seeking treatment for substance use disorders, as it eliminates the separate registration requirement for dispensing narcotic drugs for maintenance or detoxification treatment. This could make it easier for individuals to access the necessary medications for their treatment.
2. Health care practitioners, specifically those who specialize in addiction treatment, may be affected by this legislation as it changes the registration requirements for dispensing narcotic drugs. They may need to update their processes and procedures to comply with the new regulations.
3. The national education campaign included in this legislation could potentially increase awareness and understanding of substance use disorders and the importance of integrating treatment into medical practices. This could lead to more individuals seeking treatment and potentially improve the overall treatment outcomes for those with substance use disorders.
[Congressional Bills 116th Congress]
[From the U.S. Government Publishing Office]
[H.R. 2482 Introduced in House (IH)]
<DOC>
116th CONGRESS
1st Session
H. R. 2482
To amend section 303(g) of the Controlled Substances Act (21 U.S.C.
823(g)) to eliminate the separate registration requirement for
dispensing narcotic drugs in schedule III, IV, or V (such as
buprenorphine) for maintenance or detoxification treatment, and for
other purposes.
_______________________________________________________________________
IN THE HOUSE OF REPRESENTATIVES
May 2, 2019
Mr. Tonko (for himself, Mr. Lujan, Mr. Delgado, Mr. Budd, Ms. Stefanik,
and Mr. Turner) introduced the following bill; which was referred to
the Committee on Energy and Commerce, and in addition to the Committees
on the Judiciary, and Ways and Means, for a period to be subsequently
determined by the Speaker, in each case for consideration of such
provisions as fall within the jurisdiction of the committee concerned
_______________________________________________________________________
A BILL
To amend section 303(g) of the Controlled Substances Act (21 U.S.C.
823(g)) to eliminate the separate registration requirement for
dispensing narcotic drugs in schedule III, IV, or V (such as
buprenorphine) for maintenance or detoxification treatment, and for
other purposes.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ``Mainstreaming Addiction Treatment
Act of 2019''.
SEC. 2. ELIMINATING SEPARATE REGISTRATION REQUIREMENT FOR DISPENSING
NARCOTIC DRUGS IN SCHEDULE III, IV, AND V FOR MAINTENANCE
OR DETOXIFICATION TREATMENT.
(a) In General.--Section 303 of the Controlled Substances Act (21
U.S.C. 823) is amended--
(1) by striking paragraph (2) of subsection (g); and
(2) in subsection (g), as amended--
(A) by striking ``(g)(1) Except as provided in
paragraph (2), practitioners who dispense narcotic
drugs to individuals for maintenance treatment or
detoxification treatment'' and inserting ``(g)
Practitioners who dispense narcotic drugs (other than
narcotic drugs in schedule III, IV, or V) to
individuals for maintenance treatment or detoxification
treatment'';
(B) by redesignating subparagraphs (A), (B), and
(C) as paragraphs (1), (2), and (3), respectively; and
(C) in paragraph (2), as redesignated, by
redesignating clauses (i) and (ii) as subparagraphs (A)
and (B), respectively.
(b) Conforming Changes.--
(1) Subsections (a) and (d)(1) of section 304 of the
Controlled Substances Act (21 U.S.C. 824) are amended by
striking ``303(g)(1)'' each place it appears and inserting
``303(g)''.
(2) Section 309A(a)(2) of the Controlled Substances Act (21
U.S.C. 829a) is amended--
(A) in the matter preceding subparagraph (A), by
striking ``the controlled substance is to be
administered for the purpose of maintenance or
detoxification treatment under section 303(g)(2)'' and
inserting ``the controlled substance is a narcotic drug
in schedule III, IV, or V to be administered for the
purpose of maintenance or detoxification treatment'';
and
(B) by striking ``and--'' and all that follows
through ``is to be administered by injection or
implantation;'' and inserting ``and is to be
administered by injection or implantation;''.
(3) Section 520E-4(c) of the Public Health Service Act (42
U.S.C. 290bb-36d(c)) is amended by striking ``information on
any qualified practitioner that is certified to prescribe
medication for opioid dependency under section 303(g)(2)(B) of
the Controlled Substances Act'' and inserting ``information on
any practitioner who prescribes narcotic drugs in schedule III,
IV, or V of section 202 of the Controlled Substances Act for
the purpose of maintenance or detoxification treatment''.
(4) Section 544(a)(3) of the Public Health Service Act (42
U.S.C. 290dd-3) is amended by striking ``any practitioner
dispensing narcotic drugs pursuant to section 303(g) of the
Controlled Substances Act'' and inserting ``any practitioner
dispensing narcotic drugs for the purpose of maintenance or
detoxification treatment''.
(5) Section 1833(bb)(3)(B) of the Social Security Act (42
U.S.C. 1395l(bb)(3)(B)) is amended by striking ``first receives
a waiver under section 303(g) of the Controlled Substances Act
on or after January 1, 2019'' and inserting ``first begins
prescribing narcotic drugs in schedule III, IV, or V of section
202 of the Controlled Substances Act for the purpose of
maintenance or detoxification treatment on or after January 1,
2019''.
(6) Section 1834(o)(3)(C)(ii) of the Social Security Act
(42 U.S.C. 1395m(o)(3)(C)(ii)) is amended by striking ``first
receives a waiver under section 303(g) of the Controlled
Substances Act on or after January 1, 2019'' and inserting
``first begins prescribing narcotic drugs in schedule III, IV,
or V of section 202 of the Controlled Substances Act for the
purpose of maintenance or detoxification treatment on or after
January 1, 2019''.
(7) Section 1866F(c)(3) of the Social Security Act (42
U.S.C. 1395cc-6(c)(3)) is amended--
(A) in subparagraph (A), by inserting ``and'' at
the end;
(B) in subparagraph (B), by striking ``; and'' and
inserting a period; and
(C) by striking subparagraph (C).
(8) Section 1903(aa)(2)(C) of the Social Security Act (42
U.S.C. 1396b(aa)(2)(C)) is amended--
(A) in clause (i), by inserting ``and'' at the end;
and
(B) by striking clause (ii).
SEC. 3. NATIONAL EDUCATION CAMPAIGN.
(a) In General.--The Secretary of Health and Human Services, acting
through the Assistant Secretary for Mental Health and Substance Use,
shall conduct a national campaign to educate practitioners with respect
to the elimination of the separate registration requirement under
section 303(g) of the Controlled Substances Act (21 U.S.C. 823(g)), as
in effect on the day before the date of enactment of this Act, for
dispensing narcotic drugs in schedule III, IV, and V for maintenance or
detoxification treatment.
(b) Required Components.--The national education campaign under
subsection (a) shall--
(1) encourage practitioners to integrate substance use
treatment into their practices; and
(2) include education on publicly available educational
resources and training modules that can assist practitioners in
treating patients with a substance use disorder.
<all>